Current opinion in endocrinology, diabetes, and obesity · 2013
Postmenopausal osteoporosis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Diab Dima L, Watts Nelson B
Аннотация
PURPOSE OF REVIEW: The aim of this study is to provide a thorough updated review of the diagnosis and treatment of postmenopausal osteoporosis.
RECENT FINDINGS: There have been several important findings in the field of postmenopausal osteoporosis over the past 1-2 years. Fewer morphometric vertebral fractures were found in women treated for 6 years with zoledronic acid compared with those who stopped treatment after 3 years. Longer duration of bisphosphonate therapy is associated with a higher risk of atypical femur fractures. Combination therapy with teriparatide and denosumab appears to increase bone mineral density to a greater extent than either therapy alone in postmenopausal women at high risk for fracture. There are several novel therapies under investigation for the treatment of osteoporosis, which are in various stages of development. Nonadherence to osteoporosis therapies continues to be a major problem in clinical practice.
SUMMARY: There are numerous effective pharmacologic treatment options for postmenopausal osteoporosis. Bisphosphonate drug holidays continue to be an area of significant debate.
RECENT FINDINGS: There have been several important findings in the field of postmenopausal osteoporosis over the past 1-2 years. Fewer morphometric vertebral fractures were found in women treated for 6 years with zoledronic acid compared with those who stopped treatment after 3 years. Longer duration of bisphosphonate therapy is associated with a higher risk of atypical femur fractures. Combination therapy with teriparatide and denosumab appears to increase bone mineral density to a greater extent than either therapy alone in postmenopausal women at high risk for fracture. There are several novel therapies under investigation for the treatment of osteoporosis, which are in various stages of development. Nonadherence to osteoporosis therapies continues to be a major problem in clinical practice.
SUMMARY: There are numerous effective pharmacologic treatment options for postmenopausal osteoporosis. Bisphosphonate drug holidays continue to be an area of significant debate.
Предметные рубрики MeSH
Accidental FallsAgedAlendronateAntibodies, Monoclonal, HumanizedBone DensityBone Density Conservation AgentsCalcitoninCalciumDenosumabDietary SupplementsDiphosphonatesFemaleFractures, BoneHumansImidazolesMedication AdherenceMiddle AgedOsteoporosis, PostmenopausalRaloxifene HydrochlorideRisk AssessmentRisk FactorsRisk Reduction BehaviorTeriparatideVitamin DZoledronic Acid